Clinical Trials Browser

Terminated × Carcinoma, Transitional Cell × erdafitinib × Clear all

NCT05052372 2022-12-22

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell